Dexcom INC Form 4 insider transactions

DexCom Executive Vice President and Chief Legal Officer Michael Jon Brown sold 1,700 shares of common stock under a 10b5-1 trading plan.

DEXCOM's EVP and Chief Legal Officer, Michael Jon Brown, sold 1,700 shares of common stock for $64.85 per share under a pre-arranged 10b5-1 plan.

DexCom Inc. Director Albert Frederick Osterloh IV was granted 7,061 restricted stock units, vesting over three years.

Dexcom's President, CEO, and Director, Jacob Steven Leach, reported the vesting of performance-based restricted stock units and subsequent tax withholding, increasing his direct beneficial ownership.

Dexcom's EVP, Chief HR Officer Sadie Stern acquired 7,123 shares of common stock through the vesting of performance-based restricted stock units, while 2,656 shares were withheld for tax obligations.

DexCom's EVP and Chief Financial Officer, Jereme M. Sylvain, reported the vesting of performance-based restricted stock units and subsequent tax-related share withholding.

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, increased his direct ownership of common stock through the vesting of performance-based restricted stock units.

Dexcom Executive Chair Kevin R. Sayer reported the vesting of performance-based restricted stock units and subsequent tax withholding, increasing his direct beneficial ownership.

DexCom Director Richard Collins sold 2,906 shares of common stock for $59.05 per share under a pre-arranged 10b5-1 trading plan.

DexCom Director Bridgette P. Heller disposed of 1,012 shares of common stock for $58.07 per share, executed under a pre-arranged 10b5-1 trading plan.

Dexcom's President & COO, Jacob Steven Leach, acquired 18,200 shares of common stock for over $1 million through open market purchases.

DexCom Director Richard Alexander Collins sold 3,948 shares of common stock for $55.17 per share, executed under a Rule 10b5-1 plan.

DexCom Director Euan A. Ashley received a grant of 7,166 restricted stock units, vesting in three equal annual installments.

DexCom Director Kyle Malady sold 667 shares of common stock for $80.86 per share on September 5, 2025, under a pre-arranged 10b5-1 trading plan.

DEXCOM's EVP, Chief HR Officer, Sadie Stern, sold 1,466 shares of common stock for $80 per share under a pre-arranged 10b5-1 plan.

Dexcom's EVP and Chief Financial Officer, Jereme M. Sylvain, sold 4,824 shares of common stock for $74.17 per share under a pre-arranged 10b5-1 trading plan.

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, sold 500 shares of common stock for $80.29 per share under a pre-arranged 10b5-1 trading plan.

Dexcom Director Mark G. Foletta sold 2,750 shares of common stock through a pre-arranged 10b5-1 trading plan.

Dexcom's EVP and Chief HR Officer, Sadie Stern, sold 1,466 shares of common stock for $88.99 per share under a Rule 10b5-1 trading plan.

DexCom Inc. Director Mark G. Foletta sold 2,750 shares of common stock through a pre-arranged 10b5-1 trading plan.

Dexcom's Executive Vice President and Chief Legal Officer, Michael Jon Brown, sold 500 shares of common stock for $86.03 per share on July 15, 2025, under a pre-arranged 10b5-1 plan.

Dexcom Director Renee D. Gala filed an amended Form 4 to correct a previously misreported grant of 1,161 unvested restricted stock units.

Dexcom's EVP, Chief HR Officer, Sadie Stern, sold 1,466 shares of common stock for $85.06 per share on June 26, 2025, as part of a pre-arranged 10b5-1 trading plan.

DexCom Inc. Director Mark G. Foletta reported the sale of 2,750 shares of common stock at a weighted average price of $83.129 per share, executed under a pre-arranged 10b5-1 trading plan.

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, sold 500 shares of common stock for $82.8 per share on June 16, 2025, as part of a pre-established 10b5-1 trading plan.

DexCom Inc. Director Nicholas Augustinos reported the sale of 6,290 shares of common stock in two transactions in mid-June 2025, executed under a pre-arranged 10b5-1 trading plan.

Sadie Stern, Executive Vice President and Chief HR Officer of Dexcom Inc. (DXCM), reported the sale of 6,184 shares of common stock for approximately $526,300, executed under a Rule 10b5-1 trading plan.

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, sold 10,000 shares of common stock for approximately $84.28 per share, as part of a pre-established 10b5-1 trading plan.

Dexcom Inc.'s Executive Vice President and Chief Commercial Officer, Jon Coleman, has been granted 68,738 shares of common stock in the form of restricted stock units, aligning executive interests with shareholder value.

Director Rimma Driscoll reports acquisition of Dexcom stock via restricted stock units (RSUs) and disposal of shares.